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Donald E. Craven, M.D.
Intravenous drug users are the second most common risk groupfor acquired immunodefi-
ciency syndrome (AIDS) in the United States, and they accountfor approximately 25 per-
cent ofthe cases. Drug users may spread human immunodeficiency virus (HIV) by sharing
contaminated drug injection paraphernalia and through sexual contact; women who use
drugs can transmit the virus to their children. The rapid spread ofHIV in this risk group
and thefact that intravenous drug users are a sourcefor heterosexual andperinatal trans-
mission underscore the needfor immediate intervention. In addition, many drug addicts
are poor, have limited career possibilities, and lack health insurance, which leaves the
cost ofhospitalization and treatment to the public sector.
In the absence ofa vaccine or an effective chemotherapy, efforts to prevent the spread of
HIVmust befocused on education, behavior modification, and drug treatment. Drug-
treatmentprograms with a strong emphasis on HIV education should be available to all
drug users. Community outreach programs will be difficult and expensive to initiate,
because drug addicts have noformal organization or community AIDSprevention groups.
To prevent the spread ofHIV, federal, state, and local resources will have to be employed
in conjunction with a community infrastructure dedicated to stopping drugs, providing
effective drug treatment, and educating active drug users on methods ofAIDSprevention.
Intervention strategiesfor controlling the spread ofHIVamong active intravenous drug
users should include teaching them safer sex practices and encouraging them to seek drug
treatment and stop needle sharing. In addition, such strategies should be accompanied by
information about needle disinfection and access to sterile needles.
There is no area in which there is so much mystery, so much misunderstanding, and so
many differences of opinion as in the area of narcotics.
— President John F. Kennedy
Address to White House Conference on
Narcotics and Drug Abuse, September 1962
Dr. Donald E. Craven is associate professor ofmedicine and microbiology at the Boston University School of
Medicine; associate professor ofepidemiology and biostatistics at the Boston University School ofPublic
Health; and director ofAIDS Public Health Activities, City ofBoston, Boston City Hospital.
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In 1985, the report of the House Select Committee on Narcotics Abuse and Control
labeled drug abuse the number one health problem in the United States. The report
asserted that "more than 20,000,000 Americans use marijuana regularly, approximately
8,000,000 to 20,000,000 are cocaine users, about 500,000 are heroin addicts, 1 ,000,000
are regular users of hallucinogens and 6,000,000 people abuse prescription drugs." 1 The
AIDS epidemic has exponentially increased the concern over drug use. Intravenous drug
use is now the second most common risk factor for AIDS transmission in the United
States,
2 and the use of oral and intravenous drugs has been implicated in the transmission
of human immunodeficiency virus in gay men. 3
Intravenous drug users (IVDUs) are universally regarded as outcasts, and public dis-
dain toward them is widespread. Anti-narcotics crusader Richmond Hobson summarized
public sentiment toward this group nearly fifty years ago: "Most of the daylight robber-
ies, daring holdups, cruel murders and similar crimes of violence are now known to be
committed chiefly by drug addicts, who constitute the primary cause of our alarming
crime rate. Drug addiction is more communicable and less curable than leprosy. Drug
addicts are the principal carriers of vice diseases and with their lowered resistance are
incubators and carriers of the streptococcus, pneumonia, the germ of flu, of tuberculosis
and other diseases. . . . Upon this issue hangs the perpetuation of civilization, the destiny
of the world and the future of the human race." 4 In the past, society has tended to ignore
the problem of drug use, but the close association between AIDS and intravenous drug use
has escalated the problem to a level that cannot be dismissed.
In less than a decade, AIDS has become the number one public health concern in the
United States. It has had a greater impact on our health care system than virtually any
other infectious disease in our history. The issues ofAIDS touch the most sensitive nerves
of our legal, moral, and social fiber. Discussion of such subjects as patient confidentiality,
the use of the HIV antibody blood test for screening, and ways to respond to the epidemic
invariably ignite controversy. Within a short period, AIDS has transformed our traditional
public health approaches to epidemic control. 5 Because there is no vaccine or effective
chemoprophylaxis against HIV infection at the present time, epidemic control measures
must consist mainly in education and behavior modification programs. Behavior modifi-
cation will be a formidable task for all risk groups, but it will be especially difficult for
intravenous drug users.
Although the problems of drug addiction and those ofAIDS are separate, they are still
closely related, and intervention strategies must consider the two sets of problems to-
gether. This article will examine the epidemiology of HIV infection in intravenous drug
users, and will discuss selective issues and controversies surrounding the formulation of
health policy to contain the spread of HIV. Problems related to intravenous drug users in
Massachusetts, the New England state with the highest number of reported AIDS cases,
will receive special emphasis. It is painfully obvious that the solution to the spread of HIV
infection in intravenous drug users will not be quick or simple. We are facing a colossal
problem with catastrophic implications that require immediate, multifaceted, and cost-
effective intervention strategies.
Intravenous Drug Users
Between HIV-infected homosexual males and the intravenous drug user there are several
notable differences that are critical to understand (table 1). The term drug user refers to
any person who uses psychoactive substances outside the framework of the medical sys-
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Table 1
Summary of Notable General Differences Between Intravenous
Drug Users (IVDUs) and Homosexual Males (HSMs) with Infection
Due to Human Immunodeficiency Virus (HIV)
Characteristic IVDUs HSMs
Sex Male/female Male
Usual sexual preference Female Male
Race Minorities > white White > minorities
Employed No Yes
Socioeconomic class Middle/lower Middle/upper
Average educational level High school College
Health insurance None/Medicaid Private
Access to health care Limited Good
Criminal record Possible No
Social structure Fragmented Intact
Support groups Rare Available
Psychosocial problems Common Variable
Advocacy groups Sparse/ineffective Numerous/effective
Access to AIDS information Limited Good
Sources: See article notes 9, 11, 12, and 13.
tern.
6 The National Institute of Drug Abuse (NIDA) estimates that there are between
350,000 and 400,000 active intravenous drug users in the United States. Perhaps as many
as 10 million Americans have used cocaine, and estimates from NIDA suggest that most
cocaine users have injected it intravenously at least once. 7
Information on patterns of drug use has been limited to studies of patients entering drug
treatment programs. 8 Of the 11,623 clients who self-administered intravenous drugs and
who participated in the 1983 Treatment Outcome Prospective Study (TOPS) at the Re-
search Triangle Institute in North Carolina, 73 percent were male, 45 percent were white,
and 76 percent were between the ages of twenty-two and thirty-five. 9 Most of the partici-
pants were in methadone maintenance or detoxification programs or in therapeutic com-
munities. As expected, nearly all of the heroin users, compared to approximately half of
the cocaine users, administered drugs intravenously. About half of the heroin users and 20
percent of the cocaine addicts used drugs daily. These data suggest that large numbers of
intravenous drug users could be at risk for HIV.
Traditional stereotypes of heroin addicts and cocaine users are disappearing or chang-
ing io, ii, i2, is, i4, is two reasons for this are changes in the drug culture and the recent trend
toward polydrug use. Intravenous drug users comprise a wide spectrum of persons and
personalities. Characteristics of the addict may vary with the type of drug used, geo-
graphic area, social class, and the local drug culture. The addicted person may be a teen-
ager, an athlete, an artist, a businessperson, or a prostitute— in short, nearly anyone.
Drugs may be injected daily, on weekends, or at parties. The addict may inject alone, with
another person, or with a group.
Some addicts are employed and work regularly; others have a drug habit that consumes
their entire life. For some drug users, maintaining a habit that costs $100 to $400 per day
is a full-time job, one that requires "copping" (stealing and reselling) about two to four
times this amount to pay for the habit. 16 In some cases, the economics and social interac-
tions associated with the use of heroin may provide a welcome escape from routine life.
Addicts who survive on the street must be active, skillful, and clever.
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Most people do not appreciate that drug addiction is a serious psychological and physio-
logical disease. The drive to sustain a habit or to avoid opiate withdrawal is powerful, and
does not preclude stealing from loved ones or becoming involved in violent crime. Wil-
liam Burroughs, a well-known author and drug addict, referred to addiction as a disease
caused by the "junk virus": "Junk is the ideal product ... the ultimate merchandise. No
sales talk necessary. The client will crawl through a sewer and beg to buy. ... He does not
improve and simplify his merchandise. He degrades and simplifies the client. He pays his
staff in junk. ... A dope fiend is a man in total need of dope. Beyond a certain frequency
need knows absolutely no limit or control. . . . %u would lie, cheat, inform on your
friends, steal, do anything to satisfy total need." 17
Cocaine is a more social drug than heroin and therefore is more likely to be associated
with needle sharing. Because the effect of cocaine is short-lived, users often require fre-
quent injections of small doses. Groups of cocaine users may share needles and syringes
until the supply of drug is exhausted. About 40 percent of cocaine users snort the drug, 30
percent freebase, and about 20 shoot the drug intravenously (figures may vary between
cities).
18 Heroin addicts may also "shoot" cocaine intravenously 19 or use the two drugs
together ("speedballing"). In a recent study conducted in New York City, approximately
70 percent of the addicts attending a methadone maintenance clinic reported that they had
also used cocaine. 20
Cocaine holds a special appeal for the white middle-class male, who is usually em-
ployed and is well educated. The use of cocaine is often associated with bursts of energy
and high levels of productivity, followed by periods of little activity. 21 22 Many cocaine
addicts use alcohol, sedatives, or heroin to relieve the mood change that follows the co-
caine euphoria. The desire to repeat the cocaine "high" and avoid the "post-high depres-
sion" may lead to an obsession to get the drug regardless of the risk involved. 23 In a survey
of 500 cocaine users who called a hotline, 455 said they had stolen money from their
employers, family, or friends to support their habit: more than half had used up at least
Table 2
Possible Methods of Transmission of Human
Immunodeficiency Virus (HIV) in Persons Who Have
Intravenous Drug Use as a Risk Factor
Blood Transmission
Contaminated needles, syringes, or cookers
Needle sharing
Use of shooting galleries
Sexual Transmission
Homosexual male intravenous drug user
Female sexual partner of an intravenous drug user
Intravenous drug user prostitute
Perinatal Transmission
Transplacental exposure
Exposure to HIV-infected genital secretions or blood
Breast milk contaminated with HIV
Sources: See article notes 23 and 29.
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half of their savings; half were in debt; and 42 percent had lost their financial assets. 24 A
large number had also lost a loved one, a job, or a friend. Twenty-eight percent had par-
ticipated in illegal activities to obtain their drug. Clearly, drug addiction is a serious dis-
ease with many implications.
Epidemiology
Risk Factorsfor Intravenous Transmission
A drug user can transmit HIV intravenously or sexually; women who use drugs can trans-
mit the virus perinatally to the fetus or newborn (table 2). Blood transmission of HIV may
occur by using or sharing contaminated drug injection paraphernalia ("works"), such as
needles, syringes, or "cookers" (figure l). 25 A cooker is most often a bottle cap that is
used by the addict to heat tap water in which to dissolve the heroin prior to injection.
Transmission of HIV probably requires repeated exposures to small amounts of HIV on
Figure 1
Intravenous Drug Paraphernalia and Bleach Bottle
for Disinfection
Depicted are a syringe; a needle; and a "cooker" (spoon or bottle cap), in which tap water is heated to
dissolve the heroin; and cotton, which is placed in the cooker to remove particulate matter before the
drug is drawn in to the syringe. Also shown is a sample bottle of bleach, which is used by some ad-
dicts to disinfect drug paraphernalia.
351
New England Journal ofPublic Policy
Table 3
Risk Factors Associated with Acquisition and
Transmission of Human Immunodeficiency Virus
(HIV) Among Intravenous Drug Users (IVDUs) and
Their Sexual Contacts
Risk Factors Associated with IV Drug Use
Number of drug injections
Number of days of needle sharing
Number of needle-sharing partners
Number of HIV-antibody-positive needle-sharing partners
Use of shooting galleries
Sharing of cookers
Not being in drug treatment
Other Risk Factors
IVDU as sexual partner
Prostitution
No barrier precautions (use of condoms)
Geographic location (reservoir of HIV)
Minority (black or Hispanic) IVDU
Sources: See article notes 23, 27, 28, 29, and 33.
drug injection paraphernalia. 26 Seropositivity to HIV has been correlated with several risk
factors (table 3), including amount of needle sharing, number of needle-sharing partners,
and number of days of needle use. 27 28 29 30 31 HIV transmission has also been correlated
with the use of "shooting galleries." 32 33 A shooting gallery is a place where an addict goes
to shoot drugs or to have drugs administered. 34 35 36 There is usually a small fee to enter;
drug injection paraphernalia may be rented or purchased; and addicts with scarred and
damaged veins can have drugs injected by a "street doctor" (usually an addict or an ex-
addict). Unfortunately, the works that are sold, rented, or used by the street doctor may be
contaminated with HIV. Efforts to control the spread of HIV by the intravenous route
should focus on discouraging both intravenous drug use and sharing of drug parapherna-
lia; if these efforts are not successful, intravenous drug users should be taught proper
methods of disinfection or should be given access to sterile syringes.
Risk Factorsfor Sexual Transmission
It is difficult to separate intravenous spread of HIV from sexual transmission. HIV is
present in semen37 38 and in female genital secretions. 39 * Ample evidence shows that HIV
can be transmitted from males to females, and data suggest that female-to-male transmis-
sion occurs as well.
41 42 43 Transmission of HIV may not be as efficient as transmission of
other sexually transmitted diseases, 44 and seropositivity appears to be associated with
exposure to multiple sexual partners, 45 * with specific host factors, 47 or with intrinsic
differences in strains ofHIV 48 The use of condoms to prevent HIV infection has not yet
been studied in sufficient detail, but it is likely that condom use will reduce the frequency
of HIV transmission. 49 50 Strategies for containing the sexually transmitted spread of HIV
in drug users would include abstaining from sexual relations, limiting the number of sex-
ual partners, or using condoms and other types of safer sex practices. In contrast to other
risk groups, intravenous drug users need to alter behavior with respect to both intravenous
and sexual transmission of HIV.
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AIDS in Intravenous Drug Users
As of January 1 , 1988, approximately fifty thousand cases of AIDS had been reported to
the Centers for Disease Control (CDC). Of these patients, about half have succumbed to
their illness.
51 Intravenous drug use was the sole risk factor in 17 percent of the total num-
ber of cases; both intravenous drug use and male homosexuality/bisexuality were risk
factors in another 8 percent of the cases. Thus, intravenous drug use, either alone or in
combination with other risk factors, accounts for more than 25 percent of the AIDS cases
in the United States. On the basis of the revised (September 1987) CDC definition of
AIDS, 52 the number of cases has increased by about 15 percent. It is possible that more
intravenous drug users will be among these newly defined cases.
As noted above, the number ofAIDS cases among intravenous drug users varies by
geographic region. Overall, the incidence of AIDS in intravenous drug users is higher on
the East Coast than on the West Coast. New York City and the areas of New Jersey that
surround New York City have reported the highest rates ofAIDS in intravenous drug
users in the United States. 53 In fact, intravenous drug users now account for more than 40
percent of the reported AIDS cases from New York City.
In Massachusetts, as of January 1, 1988, more than twelve hundred cases ofAIDS had
been reported. 54 Intravenous drug use was the sole risk factor in 12 percent of the cases,
and 5 percent of the cases were reported among homosexual/bisexual males who also had
a history of intravenous drug use. Most Massachusetts cases have been reported in the
greater Boston area, but foci of cases have also been reported in Springfield, Holyoke,
Worcester, and New Bedford. Of great concern is the increase in AIDS cases among in-
travenous drug users which has been reported in Massachusetts over the past three years
(figure 2). In 1987 in that state, intravenous drug users accounted for 20 percent of the
AIDS cases, compared to 13 percent in 1986. The number ofAIDS cases in female in-
travenous drug users in Massachusetts is increasing dramatically, and minorities consti-
tute a disproportionate number ofIVDU AIDS cases in the state (table 4).
It is important to emphasize that reported cases of AIDS account for only a fraction of
the population who are infected with HIV. In addition, there is an extensive incubation
Figure 2
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Source: Data provided by Beverly Heinze-Lacey, AIDS Surveillance Unit, Massachusetts Department of Public
Health and Boston Department of Health and Hospitals.
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Table 4
Summary of AIDS Cases in 157 Intravenous Drug Users
According to Race and Sex Which Were Reported in Massachusetts
as of December 15, 1987
White Black Hispanic Total
(%) (%) (%) (%)
Male 26 (57) 54 (77) 40 (98) 120 (77)
Female 20 (43) 16 (23) 1 (2) 37 (23)
Total cases 46 (29) 70 (45) 41 (26) 157 (100)
Source: Data provided by Beverly Heinze-Lacey, AIDS Surveillance Unit, Massachusetts Department of
Public Health and the Boston Department of Health and Hospitals.
period before the onset of clinical disease. It is estimated that for every case of AIDS that
is reported, there are approximately fifty more cases ofHIV infection. 55
Seroprevalence data may provide more accurate information about the number of per-
sons infected with the virus. Numerous rates of HIV antibody seropositivity have been
reported. 56 Of course, the seroprevalence rate will vary with the specific type of popula-
tion sampled. For example, the prevalence of HIV antibody will probably be higher
among active drug users in the inner city than in drug users who are in drug treatment.
Seroprevalence data from New York City suggest that HIV is present in 40 percent or
more of the estimated two hundred thousand intravenous drug users there. 57 58 In Boston,
there are an estimated sixteen thousand intravenous drug users. Among eighty-nine per-
sons in the methadone treatment program at Boston City Hospital in 1986, the seropreva-
lence rate was approximately 15 percent, compared to a rate of about 28 percent for
hospitalized addicts without AIDS. 59 Therefore, the author estimates that about 25 percent
of the sixteen thousand drug users in Boston may be infected with HIV in 1988.
Intravenous Drug Use, AIDS, and Minorities
A disproportionate percentage of minorities in the United States have intravenous drug
use as the reported risk for AIDS. 60 Although minorities comprise only 20 percent of the
total population in the United States, about 40 percent of the AIDS cases have occurred in
this group. In Massachusetts, minorities constitute approximately 10 percent of the popu-
lation and approximately 25 percent of the AIDS cases. 61 Cumulative data through 1987 in
that state indicated that minorities accounted for 78 percent of the 120 AIDS cases in male
intravenous drug users and 48 percent of the cases in female intravenous drug users (table
4). The cumulative incidence ofAIDS among blacks in Massachusetts is nearly six times
that of whites between the ages of fifteen and forty-nine, and the incidence in black
women is fifteen times greater than in white women. 62 These data point to the need to
target resources and intervention efforts toward minority groups.
Women and Heterosexual Transmission ofHIV
There are approximately fifteen hundred cases ofAIDS in women in the United States, 63
and about 50 percent of these have intravenous drug use as a risk factor. In addition,
among women who have AIDS, five times as many have been sexual partners of intrave-
nous drug users as have been sexual partners of gay men. 64
Intravenous drug users represent the largest number of heterosexuals infected with HIV
in the United States. 65 These persons are an obvious bridge for heterosexual transmission
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of HIV. More than 90 percent of intravenous drug users are heterosexual, and more than
80 percent are sexually active. 66 Unfortunately, accurate data on heterosexual spread of
HIV in drug users are difficult to assess because of the confounding by drug use.
Perinatal and Pediatric AIDS
Female drug users and female sexual partners of male drug users are an important source
for perinatal transmission of HIV. 67 Nearly 30 percent of intravenous drug users are
women, and of these, nearly all are in their prime childbearing years. 68 HIV may be trans-
mitted in utero or in the period just after delivery, through contact with infected blood or
genital secretions. Breast milk has also been suggested as a mode of transmission. Infec-
tion rates of children born of HIV-positive mothers may vary from zero to 65 percent. 69 70 71
As of January 1 , 1988, more than 77 percent of the 737 cases of pediatric AIDS in the
United States had occurred in minority children, most ofwhom had mothers who were
intravenous drug users or who were the sexual contact of an intravenous drug user. 72 In
Massachusetts, 56 percent of the 18 cases of pediatric AIDS have occurred in minorities,
and most of these children have had a parent who was an intravenous drug user. 73
AIDS in Prostitutes
Male and female prostitutes who use intravenous drugs are also a major group at risk for
acquiring and transmitting HIV in the United States. 74 Approximately 30 to 50 percent of
female intravenous drug users are also involved in prostitution. 75 76 Although female pros-
titutes in Africa appear to have a high prevalence of HIV without drug use as a risk factor,
data from the United States suggest that in this country, the use of intravenous drugs was
strongly correlated with HIV seropositivity. 77 Seroprevalence rates for HIV varied from 1
to 57 percent for prostitutes, depending on the geographic region, the incidence ofAIDS
in women, the use of intravenous drugs, and the use of condoms. Rates of seropositivity
were 25 percent for black and Hispanic prostitutes who used IV drugs, compared to 7.7
percent for black and Hispanic prostitutes who did not use drugs; rates were 10.2 and 2.4
percent, respectively, for white prostitutes. 78
AIDS in Prisoners
As of 1986, 766 cases ofAIDS had been reported from correctional facilities nation-
wide. 79 Approximately 75 percent of the cases were reported from the "mid-Atlantic
region," and most have intravenous drug use as a risk factor. 80 The limited available data
suggest that the rate of transmission among all inmates is 1 percent. 81
Health Policy Issues for Controlling the Spread ofHIV
There have been as many plagues as wars in history; yet always plagues and wars take
people equally by surprise . . .
When war breaks out, people say: "It's stupid; it can't last long." But though a war
may well be "too stupid," that doesn't prevent its lasting. Stupidity has a knack of
getting its way . . .
A pestilence isn't a thing made to man's measure; therefore we tell ourselves that
pestilence is a mere bogy of the mind, a bad dream that will pass away. But it doesn't
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Unfortunately, the response of public health officials to the AIDS epidemic has been
characterized by a great deal of confusion. The issue of containing the spread of HIV
infection in intravenous drug users has been no exception, and few steps have been taken
to address it. Obviously, the problems are complex and often controversial. Part of the
controversy stems from ambivalent feelings on the part of politicians and public health
officials toward drug users, addiction, and AIDS. These feelings may translate into a lack
of strong moral, social, or economic commitment to education, treatment, and rehabili-
tation programs for intravenous drug users.
Health policy for the control of HIV in intravenous drug users needs to be targeted in
three general areas. First, specific efforts are needed to educate the public about the ex-
plosive nature of HIV infection among intravenous drug users. It must be made clear that
this group is a natural bridge for spreading the virus heterosexually and perinatally to
children. Special efforts are needed to discourage persons from trying drugs. Second,
addicts who are using drugs should be informed and urged to enter drug treatment pro-
grams. For the remaining group of active users who do not want to enter drug treatment,
there should be risk-reduction programs to stop needle sharing, teach proper disinfection
of works, provide access to sterile needles, and emphasize that HIV can be transmitted
sexually as well as by dirty needles. A summary of possible intervention strategies for
intravenous drug users is given in table 5.
Education and Risk Reduction
Education and risk-reduction programs are critical for controlling the spread of HIV in
Figure 3
Interactions Between AIDS Intervention Programs Based
on Drug Treatment, Risk Reduction, Education, and Counseling
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Table 5
Possible Strategies for Controlling the Spread of Human
Immunodeficiency Virus (HIV) Among Intravenous Drug Users (IVDUs)
Education
Education of the general public
Prevention programs targeted at schools, dropouts, and high-risk areas
Culturally appropriate education and prevention programs
Education of IVDUs about prevention and risk reduction
Emphasis on double risk of IV drug use and sexual transmission
Efforts to alter drug culture
Multifaceted programs with credibility and community outreach
Drug Treatment
Better access to drug treatment
New and more diverse treatment
More customized treatment programs
Better rehabilitation after treatment
Preferential admission of HIV-antibody-positive IVDUs
Better access to HIV testing and counseling
Special programs for pregnant addicts
Prevention of Parenteral Transmission of HIV
Needle-syringe disinfection with bleach
Access to sterile needles
Needle exchange
Sale of sterile needles without prescription
Change in state laws regarding possession of needles
Closing of all shooting galleries
Elimination of drug use in prisons
Available anonymous and confidential HIV antibody testing with support, counseling, and
education
Prevention of Sexual Transmission of HIV
Access to and/or distribution of condoms
Access to birth control
Available counseling and HIV antibody testing
Evaluation, counseling, and education of sexual partners
Legal Intervention
Strict enforcement of drug-trafficking laws
Higher penalties for possession of IV drugs
Mandatory education for drug users, prostitutes, prisoners
Mandatory education and listing of "Johns"
Sources: See article notes 9, 1 1 , 23, 27, 28, 29, 82, 86, 89, 90, 91 , 92, 93, 94, 1 01 , and 1 04.
the intravenous drug user. At the present time, it is essential that these programs be prop-
erly designed, implemented, and evaluated. Current AIDS education and risk-reduction
programs need to be expanded and integrated into existing drug treatment and community
outreach programs (figure 3). Many of these programs, however, are wrapped in a bu-
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reaucracy that may prevent effective use of resources. Designing specific intervention
programs for intravenous drug users is difficult; costly, because the programs need to be
customized; and often controversial.
While AIDS action groups in the United States have successfully educated gay men,
drug addicts are often less compliant and less interested in being educated. They also have
no advocacy group to disseminate information. Drug treatment centers appear to be the
logical site for initiating contact with drug addicts and providing them with education
about AIDS. All intravenous drug users entering treatment should be informed of HIV
transmission and transmission prevention. They can receive this information from drug
counselors or from recovered addicts who have been trained as counselors. In general,
intravenous drug users respond better to the personal approach than to being given a pam-
phlet on AIDS. Videos on risk reduction may be an even more effective educational tool.
Introductory courses on AIDS are offered to counselors and intravenous drug users on a
regular basis by the National Institute of Drug Abuse, AIDS action committees, and some
public health departments.
In many cities, there is a sense of urgency about instituting education and risk-reduction
programs while seroprevalence rates are relatively low. Thus, the risk of waiting must
be weighed against the need for scientific proof of a program's efficacy. Scientific or
well-designed studies are difficult to perform on intravenous drug users, but recent data
indicate that it is possible to educate drug users about AIDS and to modify their
behavior. 82 83 84
Knowledge ofAIDS and its routes of transmission were evident in a 1985 study of in-
travenous drug users in jail (N = 115) and in methadone maintenance (N= 146) and found
that 97 percent of both groups knew that sharing needles could transmit AIDS virus.
85Sixty percent of the intravenous drug users in methadone treatment had used risk-reduc-
tion methods, of which decreased needle sharing was the most common; 42 percent stated
that they had stopped sharing needles, and 24 percent reported decreased needle sharing.
Behavior change was less evident among incarcerated intravenous drug users; 23 percent
stated that they had stopped needle sharing, and 38 percent reported decreased needle
sharing. Data from Friedman et al. in New York City found that 59 percent of the intrave-
nous drug users interviewed had adopted new behaviors, such as using clean needles,
disinfecting needles, and reducing needle sharing. 86 Further data from New York and New
Jersey indicate that drug users appear to be switching from injecting cocaine and heroin to
smoking it. 87 In San Francisco, AIDS is a topic of "grave concern" for intravenous drug
users. Biernacki and Feldman have reported that intravenous drug users want to learn how
to protect themselves and, more specifically, how to sterilize drug paraphernalia. 88
Efforts to reach IVDUs not in treatment are necessarily labor-intensive. To be effec-
tive, such efforts require establishing intervention programs in such places as hospitals,
clinics, jails, prisons, and court-mandated rehabilitation centers, and at welfare and un-
employment offices. Participation in an education program on AIDS risk reduction
should be mandated for persons charged with soliciting or prostitution and as a condition
for release from jail or prison. The message at each site must be clear, concise, and non-
judgmental. It can be delivered personally, by video, or— probably less effectively —
through well-designed pamphlets. Messages about AIDS prevention should be displayed
on community billboards and on signs in stores, subways, and buses. The messages
should discourage drug use, provide access to help, and, where it is culturally appropri-
ate, be posted in foreign languages.
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Many drug users are aware that sharing needles and using contaminated works present
risks. However, the possibility of acquiring or transmitting HIV sexually is not widely
appreciated among this group, and therefore sexual preventive strategies are not com-
monly used. Specific efforts will be required to teach intravenous drug users that unpro-
tected sexual intercourse, exposure to multiple sexual partners, and ignoring safer sex
guidelines are important factors for HIV transmission. This may be the most difficult task
to accomplish.
Community outreach programs that educate and encourage active drug users to seek
drug treatment need to be established. 89 Health officials in New Jersey have successfully
linked risk reduction for AIDS with drug treatment by distributing coupons that addicts
can use for drug detoxification. 90 These coupons eliminate co-payment by the intravenous
drug user for drug treatment. Recovered drug addicts can be trained as health educators
and can be used to disseminate information about AIDS in the drug-using community.
The message should be simple and nonjudgmental: Stop drugs and seek treatment; don't
share needles, syringes, or cookers; use bleach to disinfect all drug paraphernalia.
Mobil vans appear to offer an effective method of community outreach. They are less
costly than traditional programs but need to be further evaluated. In Amsterdam, metha-
done and information about AIDS are distributed by van, 91 and in New Jersey, mobil vans
are staffed by physicians and social workers who provide medical information and refer-
rals.
92 Because intravenous drug users often congregate in certain areas in the city, mobil
vans may provide the optimal vehicle for control of HIV among this population.
Recently, the National Institute of Drug Abuse provided several community outreach
demonstration projects with funds to conduct comprehensive prevention programs for
intravenous drug users. 93 These programs will stress the importance of avoiding drugs,
seeking drug treatment, disinfecting drug paraphernalia, and practicing safer sex. Al-
though it is not clear what impact these programs will have on the course of the AIDS
epidemic in this population, the approach seems promising, in that education and preven-
tion are the only tools currently available. Failure to initiate these prevention programs,
particularly when seroprevalence rates are low, could prove to be a costly mistake. 94
The schools are of critical importance as a locus for disseminating information about
AIDS. Special efforts should be made to reach school dropouts. In the Boston Public
Schools, more than 40 percent of the students who start high school do not finish. This is
probably the group who are most at risk for running away, starting to use drugs, or engag-
ing in prostitution as a means of support; thus, individuals in this group are probably at
the highest risk for contracting AIDS.
Grants from the Centers for Disease Control to establish AIDS educational programs in
schools have been awarded to twelve cities, including Boston. Multifaceted intervention
— including traditional methods of teaching, peer teaching, the use of videos, and so on —
is needed in order to provide basic information about AIDS and HIV infection. Appropri-
ate and timely intervention may provide an effective deterrent against dropping out and
thus against acquiring HIV infection.
Drug Treatment Programs
Access to drug treatment is a cornerstone for controlling the spread of HIV. Drug treat-
ment programs are the most logical site to begin education and risk-reduction programs
for intravenous drug users. Many drug treatment programs, however, have not instituted
effective AIDS education, nor are they equipped to care for HIV-infected patients and
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their psychosocial needs. In Massachusetts, opportunities for drug treatment are insuffi-
cient, and there are long waiting periods for different treatment facilities, especially for
women, who traditionally have had a more difficult time finding placements in rehabilita-
tion programs.
Fortunately, intravenous drug users appear to fear AIDS enough to change or modify
their behavior and reduce risk by entering drug treatment. According to Des Jarlais et al.
,
more than 50 percent of the drug users seeking drug treatment cited fear ofAIDS as one
reason for entering treatment. 95
In New York City, about 100 drug treatment programs care for thirty thousand persons,
which accounts for about 15 percent of the total number of addicts there. 96 In Boston, there
are an estimated sixteen thousand intravenous drug users and about 900 treatment slots.
There is a severe shortage of drug treatment facilities in nearly all U.S. cities, owing in
large part to insufficient funds, lack of treatment sites, and poor use of existing facilities.
Nationally, methadone maintenance programs have been the mainstay of outpatient
treatment programs for the past twenty years. 97 Methadone does not produce sedation or
euphoria but reduces the craving for narcotics. In essence, methadone stabilizes the life of
many addicts, and removes them from the daily hustle of the search for drugs. The coun-
seling and support that accompany methadone treatment are a critical part of most pro-
grams. Methadone is dispensed daily in most clinics, and is administered under the
observation of clinic staff. Many clinics monitor urine samples of patients to determine
whether the intravenous drug user is still injecting drugs, because some addicts continue
to use drugs while they are on methadone.
In Amsterdam, methadone is distributed cost-free by mobile van. Addicts are carefully
observed to make certain that they ingest the drug. 98 This type ofprogram appears cost-
effective; facilitates access to drug treatment; maintains contact with the addict; and obvi-
ates the problems of establishing detoxification or methadone maintenance clinics in the
neighborhood. Mobil vans may not provide the necessary social support, but can refer
patients to Narcotics Anonymous or other groups. It is questionable whether this type of
program would be accepted in the United States.
There is a great deal of controversy in the United States about whether the aim of treat-
ment should be methadone maintenance or complete nonuse of drugs, particularly in view
of the high relapse rates and continued drug use among persons on methadone mainte-
nance. 99 Despite the high relapse rates, Dole and Nyswander report that the lives of many
patients who are on methadone maintenance are more stable and more productive, since
the patients are free of the constant craving for heroin and thus have stopped engaging in
the criminal activities associated with its use. 10° The heroin addict may not be medically
cured, but if he is integrated into society and is less likely to contract or spread AIDS
virus, the treatment should be considered successful. 101 102
Testingfor HIVAntibody
Because of the dearth of drug treatment slots, many public health and drug rehabilita-
tion programs have decided to selectively admit addicts who are HIV-antibody-positive.
This provides an incentive for voluntary HIV testing, but, ironically, access to testing is
limited.
The importance of HIV testing as an impetus for the intravenous drug user to modify or
change behavior is unclear at this time. Many public health officials argue that all intrave-
nous drug users should consider themselves HIV-positive, refrain from sharing needles,
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and practice safer sex. Others argue that an individual's knowledge of his or her HIV
antibody status may reinforce the use of condoms, limit the number of sexual partners,
and eliminate the sharing of drug paraphernalia. Studies in gay men and limited studies in
intravenous drug users suggest that there is a wide spectrum of behavioral responses to
HIV testing. 103 104 105 106 Recent data from Kings County Hospital in Brooklyn reveal a
wide range of psychological reactions to HIV testing in intravenous drug users, and indi-
cate that psychological reactions are apparent more frequently and are more severe in
female intravenous drug users than in gay men. 107 Many of these female intravenous drug
users had a documented increase in drug use following HIV testing. The use of voluntary
HIV testing for drug users in treatment remains moot and requires further evaluation.
In general, intravenous drug users have not used the state-run alternative HIV test sites,
which offer free and anonymous blood testing for HIV, perhaps because of the need to
make appointments for testing several weeks in advance. 108 In order to improve access to
HIV antibody testing for drug users, the Massachusetts Department of Drug Rehabilita-
tion and the Boston Department of Health and Hospitals have opened an anonymous drop-
in HIV counseling and testing program called Project Trust at Boston City Hospital for
intravenous drug users, their sexual contacts, needle-sharing partners, and families. Proj-
ect Trust also provides education, support groups, and referral for drug treatment.
With respect to programs for HIV antibody testing, it is important to realize that the
screening test for HIV has limitations and that false-positive and false-negative results
may be obtained. 109 The number of false-positive screening tests in intravenous drug users
is likely to be lower than in healthy blood donors, but the number of false-negative tests
would probably be greater.
HIV antibody testing in pregnant intravenous drug users raises particular issues. In
Boston, New York City, and New Jersey, pregnant addicts are given priority for treatment
slots, and some drug treatment programs are specially equipped to deal with the pregnant
addict. However, testing for HIV may have an adverse effect on the addicted mother.
Cancellieri et al. suggest that approximately 44 percent of their pregnant addicts who had
HIV testing had serious psychiatric sequelae and increased their use of "crack" during
their pregnancy. 110 Four of the sixty HIV-tested patients who were followed in the study
required psychiatric hospitalizations for acute psychoses or suicidal or homicidal behavior
following their binges with cocaine. In addition, pregnant intravenous drug users often
avoided testing until after their abortion. In our experience at Boston City Hospital and in
the experience of others, many HIV-seropositive pregnant intravenous drug users in
whom an elective abortion is possible choose to continue their pregnancy, in spite of the
risk of fetal infection . "-1, m
Voluntary HIV testing, with appropriate counseling, should be made available to all
prisoners and their sexual contacts. However, few programs for voluntary testing have
been established in prisons, and data concerning the acceptance and efficacy of those
programs which do exist are sparse.
In many U.S. cities, prostitutes have access to voluntary HIV blood testing in clinics for
sexually transmitted diseases. In some U.S. states, such as Nevada, and in Amsterdam,
licensed prostitutes must routinely be screened for HIV antibody. " 3 In data that have been
gathered on the subject of prostitution in the United States, HIV seropositivity has corre-
lated with intravenous drug use and absence of condom use. 114 Because prostitutes are a
sexually active population, it would be reasonable for health departments to set up educa-
tion and voluntary testing programs for them and to work with prostitutes' unions, where
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they exist, in this process. In New Jersey, women arrested for prostitution undergo man-
datory HIV testing. Some public health officials believe that educational programs and
voluntary testing should be offered to "Johns," or individuals caught soliciting.
Disinfection ofDrug Paraphernalia
The primary emphasis of all educational materials for intravenous drug users is to stop
using drugs and seek drug treatment. Secondarily, there should be a clear message not to
share needles, to stay away from shooting galleries, and, if necessary, to disinfect needles
and syringes with bleach. Given the limited access to needles and syringes in most U.S.
states, many public health officials have supported efforts to distribute educational mate-
rial on proper disinfection of drug paraphernalia. Limited laboratory data indicate that
HIV is killed by heat; by many household disinfectants such as bleach and rubbing alco-
hol; by spirits such as vodka or wine; and by dish-washing detergent. 115 116 Boiling sy-
ringes is inconvenient and removes the silicon lubricant from the plunger. Therefore, use
of Clorox has been recommended as an effective, safe, and convenient method of disin-
fection. Bottles of household bleach, with instructions for proper use, are now being dis-
tributed in Massachusetts, New Jersey, New York, California, and Maryland, along with
hotline numbers that can be called for information about disinfection procedures.
Access to Sterile Needles and Syringes
Data from Des Jarlais et al. indicate that there is a demand for sterile needles in New
York,
117
but laws limiting access to needles and syringes prohibit the sale of needles with-
out a prescription. Heated debates are in progress over the importance of access to sterile
drug paraphernalia in limiting the spread of AIDS. Proponents of distributing free needles
and syringes or instituting needle exchange programs argue that high rates of HIV are
present in many states that limit access to free needles, and that preventing one case of
AIDS would more than pay for these programs. Opponents of the policy argue that dis-
tributing free needles would encourage intravenous drug use and would not be useful to
most addicts, because needle sharing is part of the drug culture and the means for disin-
fection are widely available.
In Canada and some European countries, needles and syringes can be purchased with-
out a prescription. In many places where this policy prevails, seroprevalence rates are
low, but whether the rates are the result of the policy or of cultural differences and a
smaller reservoir of virus is unclear. Greater access to needles and syringes in U.S. states
would require decriminalization of drug paraphernalia possession.
There are thirteen different needle and syringe exchanges in Amsterdam. 118 The latest
data indicate that 350,000 needles and syringes were exchanged there in 1986, and that
needle sharing was reduced with no attendant increase in the patient load on drug-free
treatment programs. Positive experiences with needle exchange programs have also been
reported from Sydney, Australia, and from Liverpool, England." 9 12° Investigators in
these studies emphasize that the programs provide a means of continuing education
through constant contact with active drug users who do not want to be in treatment but
who also do not want to acquire or transmit HIV. Needle exchanges are a logical site for
providing free condoms, spermicides, and leaflets on safer sex and drug use. 121 Advocates
acknowledge that these programs would reach only a portion of the drug user population
and emphasize that the approach should be incorporated into a more comprehensive strat-
egy for risk reduction.
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Quarantine
Quarantine has been a traditional means of preventing the spread of plague and smallpox.
However, in comparison to AIDS, each of these diseases had a limited incubation period,
and the duration of each was usually short. HIV infection is usually asymptomatic, and it
is not transmitted casually. Quarantining persons with HIV would require mass screen-
ing, with all of its attendant complications, including follow-up screening for false nega-
tives and an enormous amount of money to provide care for the 1 million to 2 million
people in the United States who are probably HIV-infected and who will remain infected
for life. For these reasons, and because AIDS is a preventable disease, quarantine is an
unacceptable strategy.
Cost of Treating Drug Users Who Have Aids
The cost of treating an AIDS case in the United States varies among geographic regions
and among hospitals. Estimates of the medical care costs per AIDS patient vary between
$47,000 and $147,000. 122 123 These estimates do not include indirect costs for precautions;
the cost of Azidothymidine ( > $10,000 per year); laboratory costs for transfusions; labo-
ratory expenses to monitor treatment with Azidothymidine; the costs of treating the addic-
tion; or the support services needed to care for this population. Moreover, the estimates
do not include those hospitalization costs which precede the diagnosis of AIDS. Recent
data suggest that patients with ARC and, possibly, intravenous drug users who are HIV-
positive are also more likely to have recurrent bacterial infections that require hospitaliza-
tion.
124
The CDC's projected increase in AIDS cases for 199 1, 125 coupled with the potential
rapid spread of HIV transmission among intravenous drug users, 126 translates into huge
costs for AIDS treatment, let alone for treating drug addiction. Data suggest that 30 per-
cent or more of seropositive intravenous drug users will eventually develop AIDS, 127 and
that more than 70 percent of intravenous drug users who develop ARC will require medi-
cal attention. These estimates indicate that the medical costs for treating this population
could be staggering. Furthermore, in contrast to many gay males, most heroin addicts do
not have health insurance or support systems (table 1). This results in longer hospitaliza-
tion and more costly post-hospital care, 128 and it underscores the importance of effective
health policy programs for the intravenous drug user.
Conclusion
In the absence of a vaccine or an effective chemotherapy to cure or prevent HIV infection,
efforts to prevent AIDS must focus on education and on behavior modification. The in-
travenous drug user is at risk both through drug use and through sexual contact with in-
fected partners. Moreover, the addict has to deal not only with the threat of AIDS, but also
with his or her own addiction. Intravenous drug users now comprise the second highest
risk group for AIDS in the United States. Women, children, and minorities are widely
affected as well. Therefore, intervention programs, which need to include risk-reduction
strategies and drug treatment, must explain the risk factors in each of these groups. The
challenge is formidable, and programs will need to be creative, multifaceted, and cultur-
ally appropriate. Social prejudice, political barriers, and economic constraints will only
prolong the epidemic and magnify the risk for others. s#
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